The global eisenmenger syndrome treatment market is anticipated to grow at a CAGR during the forecast period. The triad of systemic-to-pulmonary congenital cardiovascular communication, pulmonary arterial disease, and cyanosis is called Eisenmenger syndrome. The major factor that drives the market is consistent regulatory approval to the key players operating in the global market for the treatment of Eisenmenger syndrome by providing drugs, and therapy is expected to drive the market growth. for instance-
July 2021- The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US Food and Drug Administration (FDA) has approved UPTRAVI (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension in adult patients with WHO functional class (FC) II–III, who are temporarily unable to take oral therapy. UPTRAVI IV is a therapeutic option that will allow patients to avoid short-term treatment interruptions and stay on UPTRAVI therapy, as uninterrupted treatment is considered key for individuals with PAH.
Browse the full report description of “Eisenmenger Syndrome Treatment Market Size, Share & Trends Analysis Report by Drug Type (Antiarrhythmic Agents, Blood Thinning Agents, Endothelin Receptor Antagonist, and Others) by Diagnosis (Blood Tests, Electrocardiogram (ECG), Chest X-Ray, Echocardiogram, Computerized Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), and Cardiac Catheterization) and by Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/eisenmenger-syndrome-treatment-market
April 2021- The US FDA has granted a second approval to treprostinil (Tyvaso) inhalation solution, for the patines. Tyvaso DPI is the only therapy approved by the FDA for PH-ILD, when the blood pressure in the lungs is high due to a disease that causes lung scarring. Moreover, the convenience and portability of Tyvaso DPI make it an important new option for patients with WHO Group 1 PAH and with WHO Group 3 PH-ILD, with the potential for improving the quality of life for this patient population.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2021-2028
• Segment Covered- by drug type, by diagnosis, by distribution channel
• Regions Covered- North America, Europe, Asia-Pacific, Rest of the World
• Competitive Landscape includes- AstraZeneca, Bayer AG, Johnson & Johnson Pte. Ltd Pharmaceuticals Corp., Pfizer Inc., GlaxoSmithKline,Hikma Pharmaceuticals PLC, and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment/region dominates the market in the base year?
• Which segment/region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Recovery Timeline
o Deviation from the pre-COVID forecast
o Most affected region/segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Eisenmenger Syndrome Treatment Market– Segmentation
by Drug Type
by Diagnosis
by Distribution Channel
Global Eisenmenger Syndrome Treatment Market by Region
North America
• US
• Canada
Europe
• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe
Asia-Pacific
• China
• Japan
• India
• Rest of Asia-Pacific
Rest of the World
• Middle East & Africa
• Latin America
?
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/eisenmenger-syndrome-treatment-market